Role of Gene Therapy in Pancreatic Cancer-A Review

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with limited treatment options.
• Mortality rates for PDAC have stagnated for decades, increasing its impact on overall cancer deaths.
• Current treatments like chemotherapy and surgery offer limited survival benefits for most patients.

Purpose of the Study:

• To review emerging gene therapy techniques for pancreatic cancer.
• To highlight advancements in virotherapy, synthetic vectors, and gene editing for PDAC treatment.
• To discuss challenges and potential solutions in current laboratory and clinical research for gene-based therapies.

Main Methods:

• Literature review of recent advances in gene therapy for PDAC.
• Synthesis of information on virotherapy, synthetic vectors, and gene-editing technologies.
• Analysis of current obstacles and proposed strategies for overcoming them in research and clinical settings.

Main Results:

• Gene therapies, including virotherapy, synthetic vectors, and gene editing, show promise for PDAC treatment, even in advanced stages.
• These novel approaches offer new avenues beyond traditional chemotherapy and surgery.
• Significant challenges remain in the design, administration, and clinical translation of these gene-based strategies.

Conclusions:

• Emerging gene therapies represent a significant advancement in the fight against pancreatic ductal adenocarcinoma.
• Overcoming current research and clinical obstacles is crucial for realizing the full potential of these novel treatments.
• Further research and development are needed to improve efficacy and accessibility of gene therapies for PDAC patients.